Article: article from journal or magazin.
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
A look through the new therapeutic window: irbesartan
Journal of Hypertension. Supplement
Although an impressive array of efficacious antihypertensive agents are available to treat hypertension, the optimal use of these agents is limited by dose-related side-effect profiles. This is particularly the case for widely used first-line antihypertensive agents such as diuretics, beta-blockers, calcium antagonists, and alpha1-blockers; this represents a major therapeutic dilemma in treating hypertension. With the development of the angiotensin II receptor antagonists (AIIRAs), this dilemma might have been solved. Irbesartan is a long-acting AIIRA that provides dose-related efficacy with placebo-like tolerability at all clinical doses. The results of placebo and active-control trials of irbesartan have demonstrated that the agent is as effective as the leading members of major antihypertensive classes with respect to blood pressure control, while having superior tolerability. Pooled data from nine multicenter, randomized, placebo-controlled trials with irbesartan have documented no adverse events caused by dose-response. This feature could widen the traditionally narrow therapeutic window in the treatment of hypertension and point to the use of AIIRAs such as irbesartan as first-line therapy in the management of hypertension.
Antihypertensive Agents/adverse effects/pharmacokinetics/*therapeutic useBiphenyl Compounds/adverse effects/pharmacokinetics/*therapeutic useBlood Pressure/drug effectsControlled Clinical Trials as TopicDose-Response Relationship, DrugFollow-Up StudiesHumansHypertension/*drug therapy/physiopathologyReceptors, Angiotensin/antagonists & inhibitorsSafetyTetrazoles/adverse effects/pharmacokinetics/*therapeutic useTreatment Outcome
Web of science
Last modification date